Skip to search formSkip to main contentSkip to account menu

volasertib

Known as: Benzamide, N-(Trans-4-(4-(Cyclopropylmethyl)-1-Piperazinyl)Cyclohexyl)-4-(((7r)-7-Ethyl-5,6,7,8-Tetrahydro-5-Methyl-8-(1-Methylethyl)-6-Oxo-2-Pteridinyl)Amino)-3-Methoxy-, Polo-like Kinase 1 Inhibitor BI 6727 
A dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

BI 6727
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo [Retraction].
[This retracts the article on p. 2476 in vol. 6, PMID: 27904765.]. 
2018
2018
Title Phase I trial of volasertib , a Polo-like kinase inhibitor , in Japanese patientswith acute myeloid leukemia
Right © 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association… 
2016
2016
Abstract 258: Is P53 the up-and-coming predictive biomarker for volasertib treatment in NSCLC
Introduction: Polo-like kinase (Plk1), a key regulator of cell division, is considered as an attractive target for mitotic… 
Review
2015
Review
2015
[Polo-like Kinase 1 as a Target for Anti-tumor Therapy].
Individual proteins from polo-like kinase (Plk) family fulfil different but critical functions in regulating cell cycle and… 
2014
2014
Volasertib in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii
The present invention relates to the use of azacytidine or a salt thereof or a hydrate thereof and a carambola Sergio capacitive… 
2014
2014
Preparation method of Volasertib and intermediates thereof
The invention discloses a preparation method of Volasertib (I). The preparation method comprises the following step: carrying out… 
2014
2014
FDA Grants AML Drug Volasertib Orphan Drug Designation
The new drug volasertib, which is in trials for the treatment of patients with acute myeloid leukemia (AML), has been granted… 
2013
2013
Therapeutische Wirkung des Polo-like Kinase 1-Inhibitors BI 6727 in Kombination mit Bestrahlung in einem Xenograft eines humanen Plattenepithelkarzinoms am Mausmodell
und Vortrag: Krause M, Eicheler W, Kummer B, Dörfler A, Yaromina A, Baumann M (2011) Kombination von Bestrahlung und Polo-like… 
2012
2012
Volasertib. Serine/threonine-protein kinase PLK1 inhibitor, Oncolytic.
2011
2011
Volasertib seul ou en combinaison avec de la cytarabine pour le traitement de la leucémie aiguë myéloïde
La presente invention concerne l'utilisation de BI 6727 ou de l'un de ses sels ou son hydrate pour le traitement de patients…